Dapagliflozin compared to placebo in normoglycemic patients with heart failure and reduced ejection fraction (HFrEF)

Reading time less than 1 minute
This page contains 1 evidence gap
  1. Dapagliflozin compared to placebo in normoglycemic patients with heart failure and reduced ejection fraction (HFrEF)
Population:
Normoglycemic patients (≥ 18 years) with heart failure and reduced ejection fraction (HFrEF)
Intervention:
Dapagliflozin
Comparison:
Placebo
Outcomes:
Mortality, hospitalization for heart failure, symptoms, quality of life

What evidence is needed?

More primary research is needed.

What evidence is available?

Reliable systematic reviews that show evidence gaps:

Breimer L, Li M, Klang R, Olsson L. En systematisk översikt om effekt av dapagliflozin vid hjärtsvikt och normoglykemi [A systematic review on the effect of dapagliflozin in normoglycemic patients with heart failure]. Örebro: HTA-enheten Camtö; 2024. HTA-rapport 2025:75. Mer om översikten/More about the review

Reliable, but not updated, systematic reviews that show evidence gaps:

None identified

Registration number:
Published:
Research conducted after publication could potentially change the nature of the evidence.
To top

Evidence gap identifies methods or practices for which no conclusive systematic review of benefits and harms has been published. Gaps in scientific evidence appear on the SBU website to help researchers and granting agencies identify areas that are in need of research or systematic review. An additional objective is to offer healthcare and social service providers a basis for setting priorities.